A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

January 16, 2026

Study Completion Date

January 16, 2026

Conditions
Hypertrophic CardiomyopathyObstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

mavacamten

mavacamten capsules

Trial Locations (68)

1070

Local Institution - 0001, Brussels

2000

Local Institution - 0012, Frederiksberg

2650

Local Institution - 0003, Edegem

5000

Local Institution - 0013, Odense

8000

Local Institution - 0011, Aarhus

9300

Local Institution - 0002, Aalst

10016

Local Institution - 0060, New York

10032

Local Institution - 0056, New York

13100

Local Institution - 0023, Safed

15006

Local Institution - 0038, A Coruña

15213

Local Institution - 0064, Pittsburgh

18015

Local Institution - 0068, Bethlehem

19104

Local Institution - 0046, Philadelphia

22903

Local Institution - 0053, Charlottesville

23298

Local Institution - 0059, Richmond

27710

Local Institution - 0047, Durham

28034

Local Institution - 0040, Madrid

28204

Local Institution - 0071, Charlotte

28222

Local Institution - 0039, Majadahonda

30120

Local Institution - 0037, El Palmar

31059

Local Institution - 0015, Toulouse

32224

Local Institution - 0067, Jacksonville

37075

Local Institution - 0019, Göttingen

38104

Local Institution - 0073, Memphis

41009

Local Institution - 0041, Seville

44093

Local Institution - 0014, Nantes

45267

Local Institution - 0052, Cincinnati

46260

Local Institution - 0070, Indianapolis

48109

Local Institution - 0051, Ann Arbor

49503

Local Institution - 0074, Grand Rapids

50139

Local Institution - 0028, Florence

52242

Local Institution - 0049, Iowa City

52621

Local Institution - 0022, Ramat Gan

60611

Local Institution - 0050, Chicago

61231

Local Institution - 0020, Bad Nauheim

63110

Local Institution - 0048, St Louis

69120

Local Institution - 0021, Heidelberg

75013

Local Institution - 0017, Paris

75015

Local Institution - 0016, Paris

75390

Local Institution - 0061, Dallas

76100

Local Institution - 0025, Rehovot

77030

Local Institution - 0055, Houston

Local Institution - 0057, Houston

84112

Local Institution - 0062, Salt Lake City

85259

Local Institution - 0045, Scottsdale

90027

Local Institution - 0058, Los Angeles

94143

Local Institution - 0066, San Francisco

94305

Local Institution - 0063, Stanford

97239

Local Institution - 0044, Portland

98195

Local Institution - 0065, Seattle

4941492

Local Institution - 0024, Petah Tikva

6423906

Local Institution - 0026, Tel Aviv

9112001

Local Institution - 0027, Jerusalem

06520-8017

Local Institution - 0043, New Haven

02115

Local Institution - 0054, Boston

84107-5701

Local Institution - 0072, Murray

128 08

Local Institution - 0010, Prague

140 21

Local Institution - 0009, Prague

01277

Local Institution - 0018, Dresden

6229 HX

Local Institution - 0029, Maastricht

3015 CE

Local Institution - 0030, Rotterdam

40-555

Local Institution - 0033, Katowice

31-501

Local Institution - 0034, Krakow

61-848

Local Institution - 0031, Poznan

04-628

Local Institution - 0032, Warsaw

2805-267

Local Institution - 0036, Almada

1500-650

Local Institution - 0035, Lisbon

W1G 8PH

Local Institution - 0042, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | Biotech Hunter | Biotech Hunter